Overall rank by patents
#5,275
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Deciphera Pharmaceuticals, Llc
USPTO PatentsView assignee record - 65 granted patents across 7 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
65
Total patents granted
7
CPC technology areas
13.5
Avg claims per patent
+391%
5-year filing velocity
The verdict
Deciphera holds 65 US patents across 7 technology areas, rank #5,275 of 50,000 tracked assignees.
- #5,275
- of 50,000 US assignees by volume
- Top 11%
- by Innovation Score (51.9/100)
- 13.5
- avg claims per patent
- +391%
- filing velocity, last 5 yrs
Portfolio overview
Deciphera Pharmaceuticals, Llc has been granted 65 US utility patents between 2015 and 2025, placing Deciphera Pharmaceuticals, Llc at rank #5,275 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.5 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Deciphera Pharmaceuticals, Llc is one of the more focused assignees in the PatentsView dataset. By volume, Deciphera sits between Comfort Research, Llc (65 patents, rank #5,271) and Evapco, Inc. (65 patents, rank #5,279) - the closest US assignees by grant volume. The composite Innovation Score of 51.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 54 grants, compared with 11 in the 2015–2019 window, a +391% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Deciphera Pharmaceuticals, Llc's 13.5 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Deciphera Pharmaceuticals, Llc against peers pursuing similar technology classes.
Who files at Deciphera's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Comfort Research
Comfort Research, LLC
65 patents
- Cupp Computing AS
Cupp Computing AS
65 patents
- DRS Network & Ima…
DRS Network & Imaging Systems, LLC
65 patents
- Darex
Darex, LLC
65 patents
- Elite Semiconduct…
ELITE SEMICONDUCTOR MEMORY TECHNOLOGY INC.
65 patents
- Energy Recovery
Energy Recovery, Inc.
65 patents
- Envision AESC Jap…
Envision AESC Japan Ltd.
65 patents
- Evapco
Evapco, Inc.
65 patents
- Deciphera Pharmac… ◀
Deciphera Pharmaceuticals, LLC
65 patents
What this shows Deciphera holds 65 patents at rank #5,275, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Deciphera
By rank, the assignees closest to #5,275 in granted patent volume.
- Comfort Research, Llc #5,271 · 65 patents
- Cupp Computing AS #5,272 · 65 patents
- DRS Network & Imaging Systems, Llc #5,273 · 65 patents
- Darex, Llc #5,274 · 65 patents
- Elite Semiconductor Memory Technology Inc. #5,276 · 65 patents
- Energy Recovery, Inc. #5,277 · 65 patents
- Envision AESC Japan Ltd. #5,278 · 65 patents
- Evapco, Inc. #5,279 · 65 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Deciphera's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Deciphera's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
52 Top 11% higher than 89% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 6 | 9.2% |
| 2016 | 5 | 7.7% |
| 2021 | 4 | 6.2% |
| 2022 | 10 | 15.4% |
| 2023 | 13 | 20.0% |
| 2024 | 17 | 26.2% |
| 2025 | 10 | 15.4% |
Which technologies does Deciphera Pharmaceuticals, Llc patent most?
Top 7 of 7 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Accelerating
Frequently Asked Questions
How many patents does Deciphera Pharmaceuticals, Llc hold?
Deciphera Pharmaceuticals, Llc holds 65 US granted patents filed between 2015 and 2025, spanning 7 technology areas.
What is Deciphera Pharmaceuticals, Llc's Innovation Score?
Deciphera Pharmaceuticals, Llc has an Innovation Score of 51.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Deciphera Pharmaceuticals, Llc focus on?
Deciphera Pharmaceuticals, Llc's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 56 patents. The company has filed patents in 7 CPC subclasses total.
Is Deciphera Pharmaceuticals, Llc's patent filing rate increasing or decreasing?
Deciphera Pharmaceuticals, Llc's recent filing velocity is +391% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Deciphera Pharmaceuticals, Llc's patents?
Deciphera Pharmaceuticals, Llc's patents average 13.5 claims each. This falls within the standard range, providing solid legal coverage.
How is the Deciphera Pharmaceuticals, Llc patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Deciphera's 65 grants land it in the top 11% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Deciphera ranks #5,275 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.